Kenya Reports Candidozyma auris Resistant to All Major Antifungal Drugs

Scientists in Kenya documented a 28-year-old patient with a post-surgical Candidozyma auris infection resistant to all four major antifungal classes. The strain's genome carries mutations distinct from the only previously confirmed pan-resistant case from 2022, suggesting independent evolution of resistance.

• Patient's infection resisted all 4 major antifungal drug classes
• Strain mutations differ from the 2022 pan-resistant case, suggesting independent evolution
• At least 6,304 US cases in 2024; fungus documented in over 50 countries